Cardiovalve completes TARGET study enrollment as Venus Medtech prepares CE mark filing for tricuspid valve system

Venus Medtech (Hangzhou) Inc. (HKG: 2500) has reached a critical regulatory milestone with the completion of patient enrollment for the Cardiovalve TARGET study, a pivotal trial supporting the company’s CE mark application for its transcatheter tricuspid valve replacement (TTVR) system. A total of 150 patients have been enrolled, positioning the structural heart innovator to move forward with European market filing later this year. Pending regulatory approval, commercial launch across the European Union is targeted for 2027.

The successful close of the TARGET study not only signals readiness for submission but also reflects Venus Medtech’s deepening foothold in the growing TTVR segment, where non-surgical options for tricuspid regurgitation remain limited. Cardiovalve’s transfemoral approach, aimed at providing full-valve replacement through a minimally invasive procedure, has drawn interest from interventional cardiologists seeking alternatives to complex open-heart surgeries.

This achievement also sets the stage for Venus Medtech’s broader dual-valve strategy. The company has confirmed plans to initiate the AHEAD study, a CE registration trial for its mitral valve replacement system, which will evaluate safety and performance in patients with moderate-to-severe mitral regurgitation. Together, the tricuspid and mitral platforms represent two of the most complex and underserved areas in structural heart therapy, and Venus Medtech is positioning Cardiovalve as a flagship solution across both.

Why is the completion of the TARGET trial a pivotal moment for Venus Medtech in Europe?

The Cardiovalve TARGET study was designed to assess the clinical safety and technical performance of Venus Medtech’s transcatheter tricuspid valve replacement system, with the goal of securing CE mark approval from European regulators. Enrollment of 150 patients, now complete, meets the predefined threshold required to proceed with regulatory filing. This marks the transition from clinical development to regulatory engagement, a critical step in commercializing any novel heart valve technology within the European Union.

The tricuspid valve has historically been referred to as the “forgotten valve” due to its underrepresentation in research, device development, and surgical intervention. However, recent advancements in imaging, delivery systems, and anchoring mechanisms have revitalized the segment. Industry observers have noted a sharp rise in clinical and investor interest in the TTVR space, with Venus Medtech’s Cardiovalve platform emerging as one of the few full-replacement systems nearing market readiness in Europe.

With the European market typically leading early regulatory adoption for transcatheter valve therapies, completion of the TARGET trial gives Venus Medtech a first-mover advantage, especially as other TTVR platforms remain in earlier stages of testing or face anatomical limitations. Institutional sentiment around the company’s dual-track valve strategy has strengthened in recent quarters, with analysts framing the TARGET milestone as a de-risking event that increases visibility for near-term commercialization.

How does the Cardiovalve system compare to other transcatheter tricuspid valve platforms?

The Cardiovalve tricuspid platform is a full-valve replacement system delivered via transfemoral access. This distinguishes it from repair-based alternatives that focus on leaflet approximation or annular cinching, such as those developed by Abbott Laboratories or other players focused on edge-to-edge repair. In many cases, patients with severe tricuspid regurgitation are either unsuitable for repair or have experienced recurrent disease following previous intervention. Full-valve replacement is increasingly being seen as a more definitive solution in such cases.

The Cardiovalve device is designed to minimize paravalvular leakage and achieve strong anchoring without the need for myocardial fixation, a feature that improves its usability across varied anatomies. Moreover, the low-profile design allows delivery through smaller vascular access points, reducing procedural risk and expanding eligibility to patients who would otherwise be excluded from surgery.

Venus Medtech’s R&D teams, based in China, Israel, and the United States, have tailored the Cardiovalve platform with input from structural heart specialists, optimizing for both tricuspid and mitral applications. In terms of competitive differentiation, the platform’s modular approach and transfemoral consistency make it particularly suited for global deployment, including in community hospitals and mid-volume centers that lack surgical backup for high-risk patients.

What is the scope and strategic intent behind the AHEAD study for mitral valve replacement?

Following the successful enrollment in the TARGET trial, Venus Medtech is moving forward with the AHEAD study—its next pivotal trial focused on the Cardiovalve mitral system. The AHEAD study will evaluate the safety and technical performance of the transcatheter mitral valve replacement system in patients with moderate-to-severe or severe mitral regurgitation. Like the tricuspid platform, the mitral system is also designed for transfemoral delivery, allowing for a full replacement without open-heart surgery.

The mitral regurgitation segment is significantly larger in patient volume than tricuspid disease, but it presents more anatomical complexity due to the variation in mitral annular structure and the presence of calcification or prior interventions. As a result, transcatheter mitral replacement has historically lagged a few years behind the aortic and tricuspid segments in terms of successful device deployment.

Venus Medtech’s mitral platform enters this market with a differentiated valve geometry and anchoring mechanism that could expand treatable populations. The company is expected to present early data from the mitral platform at TCT 2025, where a case demonstration session titled “Transcatheter Mitral Valve Replacement Using the New Generation Cardiovalve System” will be led by Dr. Christian Frerker. This appearance is expected to provide preliminary clinical validation and stimulate interest ahead of broader enrollment.

Analysts view the mitral expansion as the logical next step in Venus Medtech’s portfolio strategy, reinforcing its ambition to become a complete structural heart solutions provider with CE-marked platforms across multiple valve positions.

How does Venus Medtech’s international model accelerate commercial readiness?

Venus Medtech has built a globally distributed innovation model, with R&D centers in Hangzhou, Israel, and the United States. This multinational setup supports regulatory alignment across jurisdictions and enhances its ability to run multi-center clinical trials with regional expertise. Cardiovalve, a fully owned subsidiary of Venus Medtech, leverages this infrastructure for rapid prototyping, physician feedback integration, and streamlined manufacturing workflows.

The company’s intellectual property portfolio includes more than 150 issued patents, many of which are tied to next-generation structural heart technologies. Venus Medtech has also invested in automated manufacturing facilities equipped to scale Cardiovalve production for global deployment. The company’s TAVR and TPVR systems, already in various commercial stages, provide synergistic value and operational experience that can be transferred to the Cardiovalve launch.

In addition to its product strengths, Venus Medtech is seen by institutional investors as an emerging leader among China-based medtech firms with true global ambitions. The structural heart space has traditionally been dominated by U.S. and European firms, but Venus Medtech is part of a new cohort of Asia-origin players that are entering mature markets through robust clinical science and international regulatory engagement.

How are capital markets and institutional investors reacting to Venus Medtech’s momentum?

Shares of Venus Medtech, listed on the Hong Kong Stock Exchange under the ticker 2500.HK, have experienced fluctuating sentiment in recent quarters as broader medtech and device segments faced macroeconomic headwinds. However, the completion of a major clinical milestone such as the TARGET trial is expected to provide a catalyst for renewed investor interest, especially among funds focused on cardiovascular innovation and CE mark trajectories.

Institutional commentary has generally framed Venus Medtech as a high-potential, medium-risk medtech name with differentiated pipeline optionality and a long runway for revenue conversion. The 2027 commercial target for the tricuspid valve platform aligns with historical regulatory timelines in Europe and provides enough lead time to establish distribution and training partnerships. If the AHEAD study proceeds on schedule, the mitral valve platform could follow a parallel or slightly delayed regulatory path, creating a potential dual launch window in the latter half of the decade.

Investors are also monitoring developments in reimbursement policy, particularly in Germany, France, and the UK—three of the largest European healthcare markets where early adoption of TTVR and TMVR technologies is expected. Analysts believe CE mark clearance would enable Venus Medtech to explore partnerships or strategic distribution agreements that could further de-risk its European rollout.

With no current disclosure on U.S. FDA engagement for Cardiovalve, investor focus remains largely on Europe and Asia in the near term. However, a successful European launch could position the company to initiate a U.S. IDE (Investigational Device Exemption) pathway in future years, should it choose to enter the American market.

What are the key takeaways from Cardiovalve’s TARGET enrollment and CE mark progress?

• Venus Medtech (HKG: 2500) has completed enrollment of 150 patients in its European TARGET study for the Cardiovalve tricuspid valve replacement system.
• The study supports a 2025 CE mark filing, with commercial launch of the Cardiovalve TTVR system targeted for 2027 across the European Union.
• The company is preparing to initiate the AHEAD study to evaluate its transfemoral mitral valve replacement system, expanding its structural heart portfolio.
• Preliminary mitral valve data will be presented at TCT 2025, indicating clinical momentum behind the company’s dual-valve strategy.
• Cardiovalve’s full-replacement, transfemoral approach aims to compete with leading U.S. and European players by offering a scalable, minimally invasive solution.
• Venus Medtech operates R&D centers in China, Israel, and the U.S., with more than 150 issued patents and a next-gen manufacturing facility supporting global expansion.
• Institutional sentiment around the TARGET milestone has improved, with analysts framing the progress as a de-risking step toward near-term commercialization.
• The company’s Hong Kong-listed shares (2500.HK) could see renewed interest ahead of CE mark approval and potential European reimbursement partnerships.